Literature DB >> 19794265

Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection.

Peiman Habibollahi1, Saeid Safari, Nasser E Daryani, Seyed M Alavian.   

Abstract

As a well-recognized clinical phenomenon, persistent detectable viral genome in liver or sera in the absence of other serological markers for active hepatitis B virus (HBV) replication is called occult HBV infection. The main mechanism through which occult infection occurs is not completely understood and several possible explanations, such as integration into human genome and maintenance in peripheral mononuclear cells, exist. Occult HBV infection has been reported in different populations, especially among patients with Hepatitis C (HCV) related liver disease. The probable impact of occult HBV in patients with chronic HCV infection has been previously investigated and the evidence suggests a possible correlation with lower response to anti-viral treatment, higher grades of liver histological changes, and also developing hepatocellular carcinoma. However, in the absence of conclusive results, further studies should be conducted to absolutely assess the impact of occult HBV contamination on the HCV related liver disease.

Entities:  

Mesh:

Year:  2009        PMID: 19794265      PMCID: PMC2981836          DOI: 10.4103/1319-3767.56089

Source DB:  PubMed          Journal:  Saudi J Gastroenterol        ISSN: 1319-3767            Impact factor:   2.485


Occult infection with hepatitis B virus (HBV), defined as persistent detectable viral genome in serum or liver while HBV surface antigen (HBsAg) is undetectable, is not a novel concept and has been described since the early 1980's.[1] The description follows the development of highly sensitive diagnostic tests able to detect minute quantities of HBV genome.[1-3] However, several other explanations for this condition, such as HBV DNA sequence alteration by mutation[4] and viral DNA integration in the host genome,[5] have also been suggested. More recently, occult HBV infection has been considered to play a role in some clinical phenomena including cryptogenic liver disease,[6] and a poor response to antiviral treatment[7] and development of hepatocellular carcinoma[8] in chronic hepatitis C virus (HCV) infected patients. In addition, chronic HCV infection, due to almost the same route of transmission, is frequently reported with occult HBV infection.[9-12] Considering the implications of occult HBV infection and the growing evidence on this subject, we have aimed to review the available data and highlight the most important points, and it's role in response to antiviral treatment in patients with chronic HCV infection.

HISTORY

In 1985, Brechot et al. reported detection of HBV Deoxyribonucleic acid (DNA) in serum or liver of patients with chronic liver disease. The authors concluded that HBV DNA multiplication might occur in the absence of any HBV conventional serologic markers.[1] This provided the trigger for a number of other studies to test the concept in other clinical situations. In 1993, persistent anti-HBc reactivity was suggested as the only sign of occult HBV infection in the absence of other serologic markers.[13] Occult HBV infection was also shown to serve as a source of post transplant HBV infection in patients who receive liver transplantation.[14] Other studies also confirmed the presence of viral genome in tissues other than liver.[15] These studies emphasized the role of so called occult HBV infection in different conditions and also the active nature of disease as a transmissible infection. Based on these preliminary results, several other studies were planned. The presence of seronegative HBV infection in patients with chronic hepatitis due to HCV was frequently reported.[1116] In 1999, Cacciola et al. studied the existence of HBV genome in patients with HCV related chronic hepatitis and reported a prevalence rate of about 33% among these patients.2 These findings suggested a coincidence for HBV and HCV infection and mentioned a possible role for occult HBV infection in the clinical and pathologic features of chronic HCV-related liver disease.

PROBABLE MECHANISMS OF OCCULT INFECTION

There are several explanations for silent or undetectable HBV infection. The development of more sensitive and improved techniques for HBV DNA detection has led to introduction of occult HBV which was not traceable earlier.[17] This is similar to the increase in the prevalence of disease with improvement of diagnostic tools and seems to be correct at least in some cases, although other possible mechanisms have also been suggested. HBV reactivation in immunosuppressed patients reveals a role for the host immune system in occult form of HBV infection. The immune system might keep the viral replication at very low levels which are not detectable by normal screening.[18-20] Likewise, hepatic cytokines such as TNF-α and IFN-β-may inhibit viral replication and activation.[2122] Integration of viral genome in human DNA and mutations modifying the viral antigens are also among the other possible theories[45] but these mutations have not been shown in other studies.[210] Tamori et al. demonstrated HBV DNA integration in human genome and suggested a role for occult HBV in accelerating the hepatocarcinogenesis in chronic hepatitis due to HCV.[5] HBV variants according to the surface genes, and different response of the host to these variants are other possible presumptions for the presence of HBV DNA in HBsAg negative patients.[4] Early viral genome integration in liver and peripheral mononuclear cells,[23] existence of immune complexes which contain HBV DNA[24] and modified immunological response in the patient[25] are among the other probable explanations. Some other studies also suggest that the presence of other viral infections such as HCV may interfere with HBV course and detection.[26-28] This hypothesis has been empowered by in vitro analysis which showed inhibition of HBV replication by NS2 and core HCV proteins.[29-32] The exact mechanism of occult infection with HBV is not fully understood, and it is feasible that the hypotheses mentioned above could all in part contribute in the course of the disease.

OCCULT HBV IN HCV PATIENTS

Several studies have reported occult HBV infection in patients with HCV related disease. However, due to a heterogeneous study population, a net conclusion linking these results is not very straightforward. Table 1 briefly describes the results of the most important studies regarding occult HBV prevalence in HCV related liver disease. The prevalence of occult HBV in different studies has been reported between zero and 52.3% among patients with diverse liver disease due to HCV infection.[93334]
Table 1

Characteristics of various studies on occult HBV in HCV-infected patients

AuthorsYearTarget populationOccult HBV prevalence (%)Comments
Cacciola[2]1999200 with chronic HCV-related liver disease 50 with unrelated to HCV33 1433 patients with occult HBV had cirrhosis compared to 19 precent without (P = 0.04)
Fukuda[22]199966 with chronic HCV-related liver disease52.3Higher prevalence for genotype 1b than in 2a (64.3% vs 28.6%, P < 0.01)
Kao[21]2002210 with HCV-related liver disease 100 healthy controls14.8 15Study concluded that occult HBV has no significance in HCV-related liver disease
Besisik[23]200333 HBsAg negative hemodyalitic patients with HCV-related liver disease33.4-
Giannini[24]2003119 with HCV-related liver disease6.7No difference in the presence of occult HBV infection was seen between various degrees of liver disease
Georgiadou[25]2004187 with HCV-related liver disease26.2HBV-DNA was neither associated with HBV markers, nor with the clinical status of HCV patients.
Khattab[26]200553 HBsAg-negative patients with chronic hepatitis C7.5Study could not show any impact of occult HBV in these patients
Goral[27]200650 HBsAg negative hemodyalitic patients with HCV-related liver disease0-
Branco[28]200746 with HCV related liver disease19.5Occult HBV infection was much more in cases with hepatocellular carcinoma
Toyoda[29]200795 patients with HCV related hepatocellular carcinoma2.1HBV infection does not appear to play an important role in hepatocarcinogenesis
Altindiş[30]200740 HCV infected hemodyalitic patients27.5Higher rates of HBV infection in hemodialysis patients
41 HCV infected non hemodyalitic patients2.4
Alencar[31]200833 patients with HCV related cirrhosis 17 patients with HCV related hepatocellular carcinoma0 5.8Study showed higher prevalence of HCV genotype 3 among Brazilian patients with cirrhosis and hepatocellular carcinoma
Miura[7]2008141 patients with chronic HCV-related liver disease5.6Study showed HBV as a risk factor for hepatocellular carcinoma development in patients with HCV
Ramia S[32]200898 HCV infected patients from different institutions 85 controls with anti-HBC antibody 85 healthy controls16.3 41 7.1As the severity of liver disease increases the rate of positivity for HBV DNA increases
Shetty[33]200856 patients with HCV cirrhosis50Occult HBV is associated with hepatocellular carcinoma
Sagnelli[34]200889 patients with biopsy proven chronic HCV41.6No association was found between occult HBV infection and the degree of liver necroinflammation and fibrosis
Characteristics of various studies on occult HBV in HCV-infected patients Several factors could be responsible for this dissimilarity among studies. The most important of all might be heterogeneity of study populations. Higher probability of acquisition for “at risk populations” such as patients undergoing dialysis for both HBV and HCV infection might lead to higher prevalence rates [35] compared to those who do not have such risk factors. A common source of transmission such as intravenous drug use is also another factor which can affect these rates. In contrast, different techniques used to detect the HBV DNA have different sensitivities so it might lead to different and incomparable results.[36-39] Regional differences in original HBV and HCV prevalence are other important factors.

SEVERITY AND HISTOLOGY OF HCV RELATED LIVER DISEASE

Several investigators have studied the relationship between severity of HCV-linked liver disease and concomitant occult HBV infection. Cacciola et al, reported a high percentage of cirrhotic patients with occult HBV and no association with chronic hepatitis.[2] In the same year, occult HBV was reported to be seen in patients with higher hepatitis activity index although this association could not reach a statistically significant level.[33] Several other studies have shown that there is no correlation between clinical outcomes and severity of liver disease and silent HBV infection[283840-43] although recent studies have contradicted earlier reports, and emphasized on the clinical impact of silent HBV in patients suffering from chronic liver disease as a result of HCV and reported that higher levels of histological changes and hepatocellular carcinoma are seen among these patients.[7844] It should be taken into consideration that most of these studies are cross sectional and therefore more precise cohort studies have to be performed to measure the real impact of occult HBV in patients with HCV linked chronic liver disease.[18]

OCCULT HBV AND HCV GENOTYPES

Some studies have shown higher prevalence of occult HBV infection in HCV genotype 1b infected patients[33] compared to HCV genotype 2a. Following these findings most other studies failed to demonstrate such relationship between the HCV genotypes and occurrence of occult HBV infection.[72840414345]

SERUM AMINOTRANSFERASES

A relationship between the associated silent HBV and chronic HCV disease and high aminotransferases levels has been suggested by preliminary studies. Fukuda et al, found higher serum alanine aminotransferase levels in occult HBV-infected patients although, the study failed to demonstrate a significant correlation.[33] To the best of our knowledge, almost none of the studies report a relationship between silent HBV infection and high aminotransferases levels in patients suffering from chronic liver disease due to HCV infection[728404144] and it can be concluded that aminotransferase level in patients with chronic HCV infection cannot predict the presence of silent HBV replication or activation.

RESPONSE TO ANTIVIRAL TREATMENT

Treatment failure in chronically infected patients with HCV has been investigated widely due to its high priority among contemporary health problems. Several factors as well as concomitant occult HBV infection were tested; the diverse results obtained throughout the studies, make it impossible to come to a convincing conclusion about the role of silent HBV. Preliminary studies showed a trend towards weaker response to interferon mono-therapy in the presence of occult HBV.[233] However, these were followed by several studies which differed in their views and emphasized a minimal role for occult HBV in occult contamination in response to interferon mono-therapy or its combination with ribavirin.[2840-4345] Due to the differing results obtained in various studies, and the absence of prospective controlled trials, it becomes imperative to perform such trials to clarify the role of occult HBV infection and its impact on anti-HCV treatment. There is dissimilarity in results obtained and no prospective controlled investigations. Hence it is of utmost importance to perform such investigations to clarify the role of occult HBV infection in response to anti-HCV treatment.

CONCLUSION

In conclusion, available data, concerning the impact and prevalence of occult HBV infection in chronically infected patients with HCV, points to a considerable concomitance which may accompany higher grades of liver involvement and poorer response to anti-viral treatment. However, due to a scarcity of well-designed cohort studies, adequate conclusions can only be arrived at following further research on the subject.
  44 in total

1.  Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients.

Authors:  K Koike; M Kobayashi; M Gondo; I Hayashi; T Osuga; S Takada
Journal:  J Med Virol       Date:  1998-04       Impact factor: 2.327

2.  Occult hepatitis B among chronic liver disease patients.

Authors:  Zahra Honarkar; Seyed M Alavian; Shahram Samiee; Kayvan Saeedfar; Mohammad R Zali
Journal:  Saudi Med J       Date:  2005-04       Impact factor: 1.484

3.  Redevelopment of hepatitis B surface antigen after renal transplantation.

Authors:  P Marcellin; E Giostra; M Martinot-Peignoux; M A Loriot; M L Jaegle; P Wolf; C Degott; F Degos; J P Benhamou
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

4.  Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.

Authors:  Izumi Hasegawa; Etsuro Orito; Yasuhito Tanaka; Noboru Hirashima; Kenji Sakakibara; Mayumi Sakurai; Seiji Suzuki; Fuminaka Sugauchi; Tomoyoshi Ohno; Ryuzo Ueda; Masashi Mizokami
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

5.  HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis.

Authors:  C Oesterreicher; J Hammer; U Koch; F Pfeffel; G Sunder-Plassmann; D Petermann; C Müller
Journal:  Kidney Int       Date:  1995-12       Impact factor: 10.612

6.  Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases.

Authors:  S P Georgiadou; K Zachou; E Rigopoulou; C Liaskos; P Mina; F Gerovasilis; E Makri; G N Dalekos
Journal:  J Viral Hepat       Date:  2004-07       Impact factor: 3.728

7.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

8.  Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients.

Authors:  M G Rumi; M Colombo; R Romeo; G Colucci; A Gringeri; P M Mannucci
Journal:  Blood       Date:  1990-04-15       Impact factor: 22.113

9.  Prevalence of low-level hepatitis B viremia in patients with HBV surface antigen-negative hepatocellular carcinoma with and without hepatitis C virus infection in Japan: analysis by COBAS TaqMan real-time PCR.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori
Journal:  Intervirology       Date:  2007-04-20       Impact factor: 1.763

10.  "Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease.

Authors:  A L Zignego; M Foschi; G Laffi; M Monti; G Careccia; R G Romanelli; E De Majo; R Mazzanti; G Buzzelli; G La Villa
Journal:  Hepatology       Date:  1994-03       Impact factor: 17.425

View more
  9 in total

1.  Serological and molecular expression of Hepatitis B infection in patients with chronic Hepatitis C from Tunisia, North Africa.

Authors:  Samar Ben Halima; Olfa Bahri; Nadia Maamouri; Imed Cheikh; Nissaf Ben Alaya; Amel Sadraoui; Ons Azaiez; Msaddak Azouz; Nabyl Ben Mami; Henda Triki
Journal:  Virol J       Date:  2010-09-15       Impact factor: 4.099

Review 2.  Hepatitis B virus infection in Latin America: a genomic medicine approach.

Authors:  Sonia Roman; Alexis Jose-Abrego; Nora Alma Fierro; Griselda Escobedo-Melendez; Claudia Ojeda-Granados; Erika Martinez-Lopez; Arturo Panduro
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

3.  Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV.

Authors:  Seyed Moayed Alavian; Seyed Mohammad Miri
Journal:  Hepat Mon       Date:  2011-02       Impact factor: 0.660

4.  Liver complications in celiac disease.

Authors:  Mohammad Reza Zali; Mohammad Rostami Nejad; Kamran Rostami; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2011-05       Impact factor: 0.660

5.  Occult hepatitis B virus infection among hemodialysis patients.

Authors:  Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

Review 6.  Emerging and re-emerging infectious diseases in Iran.

Authors:  Najmeh Parhizgari; Mohammad Mehdi Gouya; Ehsan Mostafavi
Journal:  Iran J Microbiol       Date:  2017-06

Review 7.  Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection.

Authors:  Seyed Hamid Moosavy; Parivash Davoodian; Mirza Ali Nazarnezhad; Abdolazim Nejatizaheh; Ebrahim Eftekhar; Hamidreza Mahboobi
Journal:  Electron Physician       Date:  2017-10-25

8.  Experimental chronic hepatitis B infection of neonatal tree shrews (Tupaia belangeri chinensis): a model to study molecular causes for susceptibility and disease progression to chronic hepatitis in humans.

Authors:  Qi Wang; Paul Schwarzenberger; Fang Yang; Jingjing Zhang; Jianjia Su; Chun Yang; Ji Cao; Chao Ou; Liang Liang; Junlin Shi; Fang Yang; Duoping Wang; Jia Wang; Xiaojuan Wang; Ping Ruan; Yuan Li
Journal:  Virol J       Date:  2012-08-23       Impact factor: 4.099

9.  Occult Hepatitis B (OBH) in Clinical Settings.

Authors:  Seyed Moayed Alavian; Seyed Mohammad Miri; F Blaine Hollinger; Seyed Mohammad Jazayeri
Journal:  Hepat Mon       Date:  2012-08-25       Impact factor: 0.660

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.